Vegna M L, Papa G, Defazio D, Pisani F, Coppola G, De Pità O, Puddu P, Ferranti G, Simoni R, Mandelli F
Dipartimento di Biopatologia, Umana, Università La Sapienza, Rome, Italy.
Eur J Haematol Suppl. 1990;52:32-5. doi: 10.1111/j.1600-0609.1990.tb00903.x.
23 newly diagnosed patients affected by cutaneous T-cell lymphoma were treated with sub-cutaneous interferon alpha-2a to evaluate the therapeutic efficacy and the toxicity of this agent. IFN was administered daily with dose escalation from 3 to 18 million units for 12 weeks; thereafter, patients induced into complete (CR) or partial (PR) remission were given IFN at maximal tolerated dose 3 times weekly for 6 or 9 months. The objective tumor response was observed in 17 patients (74%): 8 (35%) were CR and 9 (39%) were PR. A 74-yr-old patient died because of neutropenia and sepsis at the end of induction phase, while receiving IFN at dose of 18 million units. Disease stage is the initial feature predictive of response to IFN therapy. The dose schedule of this study was well tolerated: only 3 patients developed liver toxicity, while leukopenia was evident in 6 patients. Only 2 CR patients have relapsed, 18 and 24 months from response; the remaining 6 CR patients are in continuous complete remission with a median follow-up of 41.8 months. 6 PR patients have progressed from 8 to 17 months after response, and in the 3 PR patients not yet progressed the response duration ranges from 20 to 24 months. In conclusion, interferon alpha-2a is a very effective agent in therapy of untreated cutaneous T-cell lymphoma with an overall response rate of 74%.
23例新诊断的皮肤T细胞淋巴瘤患者接受皮下注射干扰素α-2a治疗，以评估该药物的治疗效果和毒性。干扰素每天给药，剂量从300万单位递增至1800万单位，持续12周；此后，诱导达到完全缓解（CR）或部分缓解（PR）的患者以最大耐受剂量每周3次给予干扰素，持续6或9个月。17例患者（74%）观察到客观肿瘤反应：8例（35%）为CR，9例（39%）为PR。一名74岁患者在诱导期结束时，接受1800万单位剂量的干扰素治疗时，因中性粒细胞减少和败血症死亡。疾病分期是预测对干扰素治疗反应的初始特征。本研究的剂量方案耐受性良好：只有3例患者出现肝毒性，6例患者出现白细胞减少。只有2例CR患者复发，分别在缓解后18个月和24个月；其余6例CR患者持续完全缓解，中位随访时间为41.8个月。6例PR患者在缓解后8至17个月病情进展，3例未进展的PR患者缓解持续时间为20至24个月。总之，干扰素α-2a是治疗未经治疗的皮肤T细胞淋巴瘤的一种非常有效的药物，总缓解率为74%。
